



Yoon et al. Cardiovascular Diabetology  (2015) 14:53 
DOI 10.1186/s12933-015-0219-yORIGINAL INVESTIGATION Open AccessGlycated albumin and the risk of micro- and
macrovascular complications in subjects with
Type 1 Diabetes
Hye-jin Yoon1,2†, Yong-ho Lee1,2†, So Ra Kim1,2, Tyler Hyungtaek Rim2,3, Eun Young Lee1,2, Eun Seok Kang1,2,
Bong-Soo Cha1,2, Hyun Chul Lee1,2 and Byung-Wan Lee1,2*Abstract
Background: We investigated the relationship between the glycemic indices glycated albumin (GA) and glycated
hemoglobin (HbA1c) and the progression of diabetic vascular complications [diabetic nephropathy (DN) and carotid
artery atherosclerosis (CAA)] in subjects with type 1 diabetes (T1D).
Methods: A total of 154 participants with a median follow-up of 2.8 years were enrolled in this retrospective longitudinal
study. We recruited T1D subjects who had regularly measured urine albumin-creatinine ratios and estimated glomerular
filtration rates, as well as tested HbA1c and GA levels consecutively every 3 or 6 months. A subgroup of 54 subjects was
measured repeated carotid intima-media thickness (IMT).
Results: We classified subjects into the DN progression (Group I; n = 30) with either deteriorated stages of chronic
kidney disease (n = 18) or albuminuria progression (n = 17), and the non-progression (Group II; n = 124). In multiple
logistic regression analyses, baseline albuminuria (odds ratio [OR] = 2.64, 95 % confidence interval [CI] = 1.03–6.74),
mean GA levels (OR = 2.03, 95 % CI = 1.27–3.26) were significantly associated with progression of DN. However,
there was no association with mean HbA1c (OR = 0.98, 95 % CI = 0.62–1.54). In a subgroup analysis for follow-up
measurements of carotid IMT, age was independently associated with the presence of plaque and the mean IMT.
However glycemic indices were not significantly associated with CAA.
Conclusions: Mean GA levels were more closely associated with DN progression than mean HbA1c in subjects
with T1D. However, they were not associated with the CAA.
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Current guidelines for glucose monitoring recommend
self-monitoring of blood glucose (SMBG) and glycated
hemoglobin (HbA1c) to accurately assess glycemic status
and prevent diabetic complications [1, 2]. Treatment
recommendations for type 1 diabetes (T1D) are largely
based on the results of the Diabetes Control and Com-
plications Trial (DCCT) and the follow-up of the DCCT
cohort for an additional 8 or 16 years in the Epidemi-
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unless otherwise stated.(EDIC) study [3, 4]. These trials showed that the inten-
sive treatment T1D group had lower HbA1c levels, which
reduced the risk of microalbuminuria and decreases in
the glomerular filtration rate (GFR), compared to the
conventional treatment group [2, 3, 5, 6]. Although
HbA1c is considered a gold standard measurement for
glucose monitoring in patients with diabetes, there is
growing evidence regarding the clinical relevance of
intermediate-term glycemic index of glycated albumin
(GA) for the diagnosis, evaluation for glucose status, and
prediction of diabetic complications, particularly in pa-
tients with type 2 diabetes (T2D) [7–10]. Recently, Nathan
et al. reported the clinical relevance of various glucose
biomarkers of short-, intermediate-, and long-term gly-
cemia on micro- and macrovascular complications inhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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and GA predicted retinopathy and nephropathy to a
greater extent than mean blood glucose values, and the
combination of both measurements strengthened the as-
sociation with retinopathy but not with nephropathy [11].
Based on the results of the DCCT/EDIC study [11], we
aimed to determine which glycemic index is more closely
associated with the progression of diabetic nephropathy
(DN), a microvascular complication, and carotid artery
atherosclerosis (CAA), a macrovascular complication, in
Korean subjects with T1D.
Subjects, materials and methods
Subjects and research design
In this retrospective longitudinal study, we recruited
subjects with T1D [12] who were registered in the
Severance Hospital Diabetes Registry between August
2009 and December 2013. We used the following
inclusion criteria: 1) patients who regularly measured
both their spot urine albumin-creatinine ratio (ACR)
and kidney function using estimated GFR; and 2) pa-
tients who tested HbA1c and GA levels consecutively
every 3 or 6 months. The exclusion criteria for this
study were patients with non-diabetic kidney disease,
end-stage renal disease (ESRD) on dialysis, severe liver
disease, pancreatic cancer, hyper or hypothyroidism or
acute infectious disease. We classified subjects into two
groups: the DN progression group (Group I) and the
DN non-progression group (Group II). We defined
Group I subjects with deteriorated renal function based
on estimated GFR or the advent of albuminuria greater
than 30μg/ml or the progression in albuminuria from
microalbuminuria [30-300μg/mg ACR] to macroalbu-
minuria (>300μg/mg, ACR). For deteriorated renal
function, we adopted six clinically-relevant Chronic
kidney disease (CKD) categories (≥90, 60–89, 45–59,
30–44, 15–29, or <15 mL/min/1.73m2) that were
assessed using the chronic kidney disease epidemiology
collaboration formula (CKD-EPI) [13]. We also defined
impaired renal function as decreased CKD stage. For al-
buminuria, we applied the conventional definition of micro-
albuminuria as 30μg/mg ≤ urinary ACR ≤ 300μg/mg and
macroalbuminuria as ACR >300μg/mg. In logistic regres-
sion analyses, we adhered to the previous definition of
microalbuminuria as urinary ACR more than 40μg/mg
[11]. We conducted additional analyses on the progression
of CAA to patients who were repeatedly examined for
carotid intima-media thickness (IMT). These subjects were
classified into the active CAA and inactive CAA groups.
The active CAA group was defined as patients with newly
developed carotid artery plaque(s) or persistent ones,
whereas inactive CAA group included patients with the ab-
sence of carotid IMT plaques or regressed plaques.
The Presence of retinopathy was confirmed by anophthalmologist based on funduscopic findings. The Ethics
Committee of the Yonsei University College of Medicine
approved this study protocol (2013-0917-001).
Laboratory measurements
Blood samples were collected from patients after over-
night fasting. Serum GA levels were determined using an
enzymatic method and an albumin-specific proteinase
(ketoamine oxidase), albumin assay reagent (LUCICA
GA-L, Asahi Kasei Pharma Co., Tokyo, Japan), and a
Hitachi 7699 P module auto-analyzer (Hitachi Instru-
ments Service, Tokyo, Japan) [14]. The coefficient of
variation (CV) was 1.43 %. HbA1c was measured using
high-performance liquid chromatography (HPLC) and a
Variant II Turbo (Bio-Rad Laboratories, Hercules, CA).
The reference intervals of HbA1c were between 4.0 and
6.0 %, whereas those of GA were between 11.0 and
16.0 %. The averages of HbA1c (mean HbA1c), GA
(mean GA) were determined by taking the sum of every
measured value in each individual divided by the num-
ber of values obtained throughout the study period.
Measurements of carotid intima-media thickness
Measurements of IMT in both carotid arteries were de-
scribed in detail previously [15]. Common carotid arter-
ial ultrasound examinations were conducted by two
specialized technicians using an Aloka ProSound ALPHA
10 (HITACHI, Tokyo, Japan) with a 13MHz linear probe.
IMT was defined as the distance between the media-
adventitia interface and the lumen-intima interface. Aver-
age IMT was the mean value of computer-based points in
the region, and maximal IMT was the IMT value at the
maximal point of the region. Plaques were defined accord-
ing to the Mannheim consensus [16], in which a plaque is
diagnosed when the vessel wall thickness was >1.5mm or
when the vessel wall appeared to be at least 0.5mm, or
50 % thicker, than the surrounding wall.
Statistical analyses
All statistical analyses were performed using PASW sta-
tistics software (version 20.0; SPSS Inc., Chicago, IL).
Continuous variables are described as the mean ± stand-
ard deviation (SD) or the median (interquartile range)
based on results from Kolmogorov-Smirnov tests. Cat-
egorical data are expressed as the number (n) with per-
centages. Statistical comparisons between groups with and
without DN progression were performed using Mann-
Whitney U tests or χ2 tests, which are non-parametric
statistical methods. Multivariate logistic regression ana-
lyses were used to estimate multiple correlations between
DN progression and clinical and laboratory risk factors.
We used receiver operating characteristic (ROC) curve
analyses, estimating the area under the curve (AUC) with
95 % confidence intervals (CI), to compare GA levels and
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group analyses, we determined the variables that were as-
sociated with carotid artery plaques or atherosclerosis
progression using multiple linear regression analyses. Lo-
gistic regression power calculation was carried out using
PASS software version 13.0.10 (NCSS statistical Software,
Kaysville, UT).
Results
Characteristics of the Study Participants
A total of 154 participants (69 men and 85 women;
mean age, 46 ± 15 years) with a median follow-up period
of 2.8 years were enrolled in this study. The numbers of




Age (years) 46 ± 15
Male Sex, n (%) 69 (45)
BMI (kg/m2) 22.6 ± 3.3
Obesity, n (%) 30 (19)
Duration of diabetes (years) 10.0 (3.0–15.0)
Retinopathy, n (%) 78 (51)
Hypertension, n (%) 31 (20)
ARB or ACEI use, n (%) 49 (32)
Statin use, n (%) 54 (35)
Glycemic indices
mean GA (%) 24.4 (21.5–29.0)
mean HbA1c (%) 8.7 ± 1.6
Renal function indices
Baseline ACR (μg/mg) 17.8 (7.2–71.1)
Follow-up ACR (μg/mg) 13.8 (7.5–77.9)
Baseline eGFR (mL/min/1.73 m2) 97.1 ± 22.5
Follow-up eGFR (mL/min/1.73 m2) 95.1 ± 26.0
Baseline CKD status
Stage 1 98 (64)
Stage 2 48 (31)
Stage 3 and 4 8 (5)
Biochemistry profiles
Albumin (g/dL) 4.2 ± 0.4
Total cholesterol (mg/dL) 162.0 (145.0–194.0)
Triglyceride (mg/dL) 79.0 (60.0–113.5)
HDL-cholesterol (mg/dL) 57.0 ± 15.9
LDL-cholesterol (mg/dL) 95.5 ± 34.9
Continuous variables were described as median (quartiles) or mean ± SD. N (%) for
BMI body mass index; ARB angiotensin II receptor blocker, ACEI angiotensin-convert
filtration rate, CKD chronic kidney diseasemacroalbuminuria and exhibited deterioration of CKD
stage were 18 (11.7 %) and 17 (11 %), respectively. Based
on these results, we classified subjects into the pro-
gressed DN group (Group I; n = 30) and the non-
progressed DN group (Group II; n = 124). Table 1 shows
the demographic and laboratory characteristics of the
subjects. Age, gender, and body mass indices (BMI) were
similar between the two groups. The prevalence of
hypertension and the use of anti-hypertensive medica-
tions did not significantly differ between groups. Group
I had a significantly longer diabetic duration [12.0
(10.0–18.0) vs. 8.0 (3.0–15.0) years, P = 0.004] and higher
proportion of retinopathy (70 % vs. 46 %, P = 0.018) com-
pared to Group II. At baseline, estimated GFR (91.7 ± 20.3Group I Group II
DN progression DN non-progression P
(n = 30) (n = 124)
50 ± 15 45 ± 16 0.135
11 (37) 58 (47) 0.414
23.2 ± 3.5 22.4 ± 3.3 0.256
8 (27) 22 (18) 0.306
12.0 (10.0–18.0) 8.0 (3.0–15.0) 0.004
21 (70) 57 (46) 0.018
9 (30) 22 (18) 0.202
11 (37) 38 (31) 0.663
15 (50) 39 (31) 0.056
29.3 (22.8–34.7) 24.0 (21.0–27.5) 0.004
9.0 ± 1.4 8.7 ± 1.7 0.088
47.3 (11.5–136.1) 14.6 (6.0–41.2) 0.004
134.7 (51.7–766.2) 10.6 (6.8–29.2) <0.001
91.7 ± 20.3 98.4 ± 22.9 0.079
73.9 ± 28.7 100.4 ± 22.4 <0.001
17 (57) 81 (65) 0.565
12 (40) 36 (29)
1 (3) 7 (6)
4.1 ± 0.5 4.3 ± 0.4 0.106
171.5 (149.0–195.8) 162.0 (144.0–193.5) 0.423
90.5 (71.8–118.5) 77.0 (57.0–114.0) 0.109
55.0 ± 13.7 57.5 ± 16.4 0.669
97.6 ± 31.3 95.0 ± 35.8 0.495
categorical variables
ing enzyme inhibitor, ACR albumin-creatinine ratio, eGFR estimated glomerular
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(11.5–136.1) vs. 14.6 (6.0–41.2) μg/mg, P = 0.004] differed
between the groups without and with significance, re-
spectively. However, serum creatinine levels [0.8 (0.6–0.9)
vs. 0.8 (0.7–0.9) mg/dL, P = 0.864] were the same in the
two groups. Although mean HbA1c levels (9.0 ± 1.4 vs.
8.7 ± 1.7 %, P = 0.088) were not significantly different,
the mean GA levels [29.3 (22.8–34.7) vs. 24.0 (21.0–
27.5) %, P = 0.004] were significantly higher in Group I.
Independent Association of Diabetic Nephropathy
Progression with Glycemic Indices and Risk Variables for
Chronic Kidney Disease
In univariate logistic regression analyses, DN progres-
sion was used as a dependent factor, and the variables
for mean glycemic indices and risk factors for CKD were
entered. The risk of progression of DN was 35 % higher
in subjects with a prolonged duration of diabetes and as
duration increased per 5years (OR = 1.35, 95 % CI 1.04–
1.75, P = 0.023). Higher baseline levels of albuminuria
(OR = 3.29, 95 % CI 1.44–7.48, P = 0.005) and mean GA
levels (OR = 1.73, 95 % CI 1.19–2.50, P = 0.004) were
also significantly associated with DN progression. How-
ever, mean HbA1c levels (OR = 1.24, 95 % CI 0.85–1.81,
P = 0.265) were not significantly related to the progres-
sion of DN. Moreover, hypertension, CKD stages, and
lipid profiles at baseline were not significantly related to
DN progression in this study (Fig. 1).
Glycated albumin predicted the Progression of Diabetic
Nephropathy
Based on the results in Fig. 1, multiple logistic regression
analyses were performed to predict the progression of
DN (Table 2). For multiple logistic regression analyses,
we used four statistical models with different glycemicFig. 1 Univariate logistic regression analyses of associations between clinic
diabetic nephropathyvariables: GA levels and HbA1c. In model 1, we entered
age, duration per 5years, baseline albuminuria, obesity
(BMI ≥ 25kg/m2), hypertension, baseline CKD stage, and
mean GA level. The duration of diabetes (OR = 1.44,
95 % CI 1.01–2.07, P = 0.047), baseline albuminuria (OR =
2.63, 95 % CI 1.03–6.73, P = 0.043), and mean GA level
(OR = 2.02, 95 % CI 1.28–3.17, P = 0.002) were signifi-
cantly associated with the progression of DN. In model 2
with mean HbA1c, DN progression did not independently
correlate with mean HbA1c (OR = 1.21, 95 % CI 0.79–1.85,
P = 0.390). To investigate the effects of both serum GA
levels and HbA1c on DN progression, we entered mean
GA and mean HbA1c as independent glycemic variables in
model 3. Mean GA levels (OR = 2.03, 95 % CI 1.27–3.26,
P = 0.003) remained its significance in predicting the pro-
gression of DN, whereas mean HbA1c (OR = 0.98, 95 % CI
0.62–1.54, P = 0.918) did not. In terms of retinopathy, dur-
ation of diabetes and albuminuria were significant deter-
minants for predicting retinopathy at baseline (data not
shown). However, neither mean levels of GA nor HbA1c
was associated with the presence of retinopathy at baseline
(data not shown).
Using ROC curve analyses, we calculated the AUC of
glycemic indices (mean GA and mean HbA1c) for pre-
dicting DN progression (Fig. 2). Mean GA levels showed
a larger AUC (AUC = 0.668, 95 % CI 0.55–0.78, P =
0.004) compared to mean HbA1c (AUC = 0.601, 95 % CI
0.49–0.71, P = 0.088). The AUC of mean GA levels was
statistically significant.
Association of Carotid artery atherosclerosis with
Glycemic Indices and Cardiovascular Risk Factors
Of the 154 patients with T1D, 54 subjects had repeated
carotid IMT data with a mean 2.9 year follow-up. Sub-
jects were classified into the active CAA group (n = 22)al and biochemical variables and the progression of
Table 2 Multiple logistic regression models for associations between clinical and biochemical variables and the progression of
diabetic nephropathy in a total of 154 subjects with T1D
Model 1 Model 2 Model 3
(R2 = 0.28) (R2 = 0.20) (R2 = 0.28)
Variables OR 95 % CI P OR 95 % CI P OR 95 % CI P
Age, per year 1.03 0.99–1.07 0.132 1.03 0.99–1.06 0.188 1.03 0.99–1.07 0.136
Obesity (0 = no, 1 = yes) 1.92 0.64–5.78 0.243 1.95 0.69–5.55 0.210 1.94 0.64–5.81 0.242
Duration of diabetes, per 5years 1.44 1.01–2.07 0.047 1.28 0.92–1.77 0.145 1.44 1.01–2.07 0.047
Hypertension (0 = no, 1 = yes) 2.32 0.77–6.99 0.134 2.09 0.79–5.83 0.160 2.32 0.77–6.98 0.136
Albuminuria at baseline (0 = no, 1 = yes) 2.63 1.03–6.73 0.043 2.86 1.16–7.07 0.023 2.64 1.03–6.74 0.043
Statin use (0 = no, 1 = yes) 1.89 0.74–4.88 0.186 1.49 0.59–3.75 0.403 1.91 0.73–5.01 0.188
CKD stage at baseline
Stage1 Reference Reference Reference
Stage2 0.55 0.16–1.86 0.338 0.71 0.23–2.24 0.559 0.55 0.16–1.86 0.337
Stage3 and 4 0.09 0.01–1.30 0.078 0.12 0.01–1.54 0.103 0.09 0.01–1.31 0.078
mean GA (%)* 2.02 1.28–3.17 0.002 2.03 1.27–3.26 0.003
mean HbA1c (%)* 1.21 0.79–1.85 0.390 0.98 0.62–1.54 0.918
CKD chronic kidney disease
*z-standardization of glycemic indices
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vs. 41 (35–48) years, P < 0.001] and triglyceride levels
[103.5 (63.8–189.8) vs. 72.5 (55.3–89.8) mg/dL, P =
0.004] were significantly higher in the active CAA group.
Compared with the inactive CAA group, the active CAA
group showed significantly higher ACR levels at both
baseline [28.7 (9.8–136.1) vs. 7.7 (4.1–21.5) μg/mg] and
follow-up [32.0 (10.0–108.8) vs. 9.1 (2.9–24.1) μg/mg],
as well as lower estimated GFR at baseline [87.6 (67.4–
100.2) vs. 103.1 (82.9–115.3) mL/min/1.73m2, P = 0.008]Fig. 2 Receiver operating characteristic curve of mean HbA1c and
GA levels for predicting diabetic nephropathy progressionand follow-up [86.9 (69.8–96.8) vs. 102.7 (83.6–112.8)
mL/min/1.73m2, P = 0.030] (Additional file 1: Table S1).
We used the multiple logistic regression model (model
A) for carotid artery plaques and the multiple linear re-
gression model (model B) for follow-up mean carotid
IMT values to determine the clinically independent vari-
ables that were associated with carotid artery plaques. In
both models, only age (model A: OR 1.20, 95 % CI 1.05–
1.36, P = 0.007, and model B: standardized β = 0.58, P <
0.001) was significantly associated with CAA. In these
models, glycemic indices, including mean GA levels and
mean HbA1c, and renal function related variables were
not significantly related to CAA (Table 3).
Discussion
This study focused on the association between glycemic
indices and the progression of diabetic micro- and
macrovascular complications in Korean subjects with
T1D. The availability of longitudinal measurements for
intermediate- and long-term glycemic indices, as well
as for diabetic micro- and macrovascular complica-
tions, enabled us to investigate the associations be-
tween glycemic indices (GA levels and HbA1c) and the
progression of DN and CAA in T1D. The longitudinal
nature also conferred the availability of mean glycemic
indices as time-dependent covariates.
Conventionally, DN is defined as a progressive kidney
disease characterized by persistent albuminuria, in-
creased blood pressure, and a continuous decline in
GFR. It is a common cause of ESRD and has a high risk
of cardiovascular morbidity and mortality [17, 18]. Al-
though persistent albuminuria is a strong predictor for
Table 3 Associations of the cardiovascular risk factors with carotid artery atherosclerosis in a subgroup of 54 subjects with T1D
Model A Model B
Presence of plaque at follow up Follow up IMT mean value
Variables OR 95 % CI P STD β P
Age, per year 1.20 1.05–1.36 0.007 0.58 <0.001
Sex (0 = female, 1 =male) 0.92 0.13–6.47 0.933 0.01 0.915
Obesity (0 = no, 1 = yes) 6.90 0.73–65.64 0.093 0.13 0.251
Duration of diabetes, per 5years 1.39 0.74–2.61 0.301 −0.02 0.886
Hypertension (0 = no, 1 = yes) 5.20 0.60–44.98 0.135 0.03 0.801
Albuminuria at baseline (0 = no, 1 = yes) 4.61 0.60–35.57 0.143 0.02 0.876
Baseline eGFR , per 1mL/min/1.73 m2 1.05 0.97–1.12 0.219 −0.09 0.590
LDL-cholesterol, per 1mg/dL 0.98 0.94–1.02 0.252 0.15 0.268
mean GA (%)* 0.43 0.09–2.00 0.280 −0.16 0.124
mean HbA1c (%)* 0.53 0.21–1.36 0.187 0.16 0.168
Model A: multiple logistic regression analysis, Model B: multiple linear regression analysis
eGFR estimated glomerular filtration rate, IMT intima-media thickness, STD standardized
*z-standardization of glycemic indices
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of progression to proteinuria in T1D subjects with
microalbuminuria [19]. Furthermore, the progression of
albuminuria might be critical but not essential in CKD
progression [20]. Based on these findings, in this study,
we defined the progressed DN group as either deterio-
rated estimated GFR based CKD stages or the advent of
microalbuminuria or progression of albuminuria stage
[21, 22]. In addition, based on our previous cross-
sectional study [23], we classified the available subjects
into active and inactive CAA progression groups.
Considering the role of GA as a short-term (3-week)
glycemic parameter, GA can reflect glucose fluctuation
and postprandial glucose more sensitively than HbA1c
[24, 25]. To investigate the association between the gly-
cemic indices and the progression of diabetic micro- and
macrovascular complications, we used the following ana-
lyses. To validate the reliability of glycemic indices in
this study, we assessed correlations between HbA1c and
GA levels at baseline. As expected, HbA1c and GA levels
were highly correlated at baseline (r = 0.631, P < 0.001).
Next, we examined the association between glycemic in-
dices and progression of DN and CAA. Recent studies
reported that serum GA is closely associated with, or
predicts, DN and diabetic retinopathy in patients with
both T2D [26, 27] and T1D [11]. However, the clinical
implications of GA on the presence or progression of
CAA was not noted T1D patients [11] but was observed
in T2D patients [7, 15]. Furthermore, GA but not HbA1c
was associated with coronary heart disease in the
Chinese population with exclusion of T1D [28]. In a
case-cohort subpopulation of the DCCT [11], HbA1c
and GA levels had similar associations with retinopathy
and nephropathy, but only HbA1c was significantly as-
sociated with cardiovascular disease. Selvin et al., alsodemonstrated the significant association of GA with inci-
dent CKD in subjects with both type 1 and 2 diabetes even
after adjustment with HbA1c [29], indicating that GA can
work well for predicting microvascular complications [30].
This is supported by another study showing increased
levels of GA in subjects with retinopathy [31]. This study
has three main findings: first, diabetes duration fundamen-
tally affected the progression of DN; second, albuminuria
levels, not baseline CKD stage, were significantly related to
DN progression; third, mean GA, but not mean HbA1c,
were significantly associated with progression of DN. Re-
garding CAA as a macrovascular complication, HbA1c and
GA levels were not related to the progression of carotid
IMT. Consistent with previous studies [21, 22], age was
the only factor that was significantly associated with
CAA in this study.
Although there was no association between HbA1c and
DN, this does not imply that poor glycemic control does
not affect diabetic microvascular complications. Consid-
ering glycemic control and the clinical outcomes in
T1D, the DCCT/EDIC study clearly confirmed that pa-
tients with T1D in the intensive treatment group with
lower HbA1c levels had reduced risks of microalbumi-
nuria and declines in GFR compared to patients in the
conventional treatment group [2, 3, 5]. DN progression
was assessed using multiple logistic regression models,
and the association with mean HbA1c was further atten-
uated once mean GA levels were also entered; however,
mean GA levels might be augmented when HbA1c was
considered [11]. These findings suggest that GA mea-
surements might be helpful in predicting DN in subjects
with T1D.
With respect to the effects of GA on the progression
of DN and CAA in T1D, we hypothesize that different
complications might be affected by hyperglycemia. By
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insulin deficiency; however, the primarily underlying
pathophysiologic mechanism of T2D is hyperinsulinemic
insulin resistance [32]. Clinically, DN is more prone to
glucotoxicity than insulin resistance. In addition, meta-
bolic syndrome, primarily caused by insulin resistance, is
a known risk factor for DN [33]. However, in this study,
BMI and triglyceride levels were not related to DN pro-
gression. The low BMI of patients (Group I; mean BMI =
23.2 kg/m2 and Group II; mean BMI = 22.4 kg/m2) in our
study population might account for the insignificant asso-
ciation between DN progression and variables for meta-
bolic syndrome. Therefore, the statistical association of
GA with the progression of DN but not with CAA is not
surprising. We postulate that the clinical relevance of GA
levels on the development of CAA in T1D might be in
contrast to the presence of insulin resistance observed in
T2D. Based on these findings, we postulate that gluco-
toxicity might be important for the progression of DN,
but insulin resistance might play a major role in the de-
velopment of CAA regardless of diabetes type.
With respect to results on the relationship of glycemic
indices with the progression of DN and CAA, our
findings generally coincide with the data from previous
studies; however, some conflicts remain. Possible expla-
nations for our differing results are the differences in
the baseline characteristics of patients and the longitu-
dinal observation study design. The enrolled subjects
had primarily adult-onset T1D (average age 46 years
with 10 years of diabetes duration) with glycemia that
was not well controlled (mean HbA1c, 8.7 %). They
were followed up for a median of 2.8 years to assess the
progression of DN and CAA. Although mean creatinine
(0.8 mg/dL) and estimated GFR (97.1 ml/min/1.73m2)
levels were in the apparently normal range, this study
included 8 subjects (5 %) with CKD (except for ESRD
on dialysis). Because HbA1c does not reflect blood glu-
cose levels accurately in subjects with advanced renal
disease [10], GA levels might more accurately reflect
the glycemic status in these subjects. These differences
in baseline characteristics and study design might ac-
count for the different results from previous studies.
This study had some limitations. First, the follow-up
period was relatively short (2.8 years) and small number
of T1D subjects which led to have not enough estimated
power for this study (68 %). Second, we did not analyze
the influence of smoking habits or medication status
that could affect GA levels. Third, we did not measure
blood pressure repeatedly; therefore, the effect of con-
tinuous blood pressure was not included. Despite these
limitations, our study population consists primarily of
patients with adult-onset T1D, which is not a common
study population in the T1D research field. The tools for
assessing glycemic indices (HbA1c and GA) and diabetescomplications (ACR and carotid IMT) are well docu-
mented. Moreover, this is the first longitudinal observa-
tion study for Asian subjects with T1D that examines
the clinical relationship between glycemic indices and
the outcomes of diabetic complications.
In summary, we investigated the association of various
glycemic indices and the progression of DN and CAA in
Korean subjects with T1D. Mean GA levels, rather than
mean HbA1c, are more closely associated with the pro-
gression of DN. However, all glycemic indices were not
associated with the progression of CAA. In conclusion,
we suggest that GA levels, rather than HbA1c, are associ-
ated with DN progression and confer clinical relevance
in the management of T1D. Well-designed prospective
studies enrolling larger populations are warranted.
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